The first pan-coronavirus ("universal") vaccine Phase 1 clinical trial results are encouraging for eliciting broad sarbecovirus, SARS-CoV-2 variant immune response
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
May 15, 2024 at 11:12 PM
The first pan-coronavirus ("universal") vaccine Phase 1 clinical trial results are encouraging for eliciting broad sarbecovirus, SARS-CoV-2 variant immune response
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
8/10
...Sarbecovirus-Familie identisch (konserviert) sind.
...Sarbecovirus-Familie identisch (konserviert) sind.
July 23, 2026 at 10:24 AM
8/10
...Sarbecovirus-Familie identisch (konserviert) sind.
...Sarbecovirus-Familie identisch (konserviert) sind.
Study: An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity
www.nature.com/articles/s41...
www.nature.com/articles/s41...
An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity - npj Vaccines
npj Vaccines - An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity
www.nature.com
July 18, 2025 at 2:26 AM
Study: An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Saskatoon lab secures $24 million grant to create 'holy grail' pan-sarbecovirus vaccine thestarphoenix.com/news/local-n... @brodylangager.bsky.social
Get weekly updates: CanadaHealthwatch.ca/newsletter 🍁
Get weekly updates: CanadaHealthwatch.ca/newsletter 🍁
January 27, 2025 at 11:18 PM
Saskatoon lab secures $24 million grant to create 'holy grail' pan-sarbecovirus vaccine thestarphoenix.com/news/local-n... @brodylangager.bsky.social
Get weekly updates: CanadaHealthwatch.ca/newsletter 🍁
Get weekly updates: CanadaHealthwatch.ca/newsletter 🍁
What we should be doing, but we're not:
"Arming the immune system for the next zoonotic coronavirus spillover"
A nasal dendritic-cell targeting vaccine that prevents viral transmission vs pan-sarbecovirus clades (i.e. all coronaviruses, irrespective of variants)
www.jci.org/articles/vie...
"Arming the immune system for the next zoonotic coronavirus spillover"
A nasal dendritic-cell targeting vaccine that prevents viral transmission vs pan-sarbecovirus clades (i.e. all coronaviruses, irrespective of variants)
www.jci.org/articles/vie...
March 18, 2026 at 12:46 AM
What we should be doing, but we're not:
"Arming the immune system for the next zoonotic coronavirus spillover"
A nasal dendritic-cell targeting vaccine that prevents viral transmission vs pan-sarbecovirus clades (i.e. all coronaviruses, irrespective of variants)
www.jci.org/articles/vie...
"Arming the immune system for the next zoonotic coronavirus spillover"
A nasal dendritic-cell targeting vaccine that prevents viral transmission vs pan-sarbecovirus clades (i.e. all coronaviruses, irrespective of variants)
www.jci.org/articles/vie...
'Furthermore, vaccinated and subsequently challenged cohorts failed to transmit the virus to naïve animals, demonstrating a *complete block of onward transmission*'.
* my emphasis.
Extraordinarily promising research.
www.nature.com/articles/s41...
* my emphasis.
Extraordinarily promising research.
www.nature.com/articles/s41...
A single-dose amber codon carrying live attenuated vaccine elicits pan-sarbecovirus immunity and blocks SARS-CoV-2 transmission - npj Vaccines
npj Vaccines - A single-dose amber codon carrying live attenuated vaccine elicits pan-sarbecovirus immunity and blocks SARS-CoV-2 transmission
www.nature.com
August 8, 2026 at 11:37 AM
'Furthermore, vaccinated and subsequently challenged cohorts failed to transmit the virus to naïve animals, demonstrating a *complete block of onward transmission*'.
* my emphasis.
Extraordinarily promising research.
www.nature.com/articles/s41...
* my emphasis.
Extraordinarily promising research.
www.nature.com/articles/s41...
🚨 New Publication!!!
I’m thrilled to share our latest study, “Clonotype-Enriched Somatic Hypermutations Drive Affinity Maturation of a Public Human Antibody Targeting an Occluded Sarbecovirus Epitope”.
www.cell.com/cell-reports... [1/4]
I’m thrilled to share our latest study, “Clonotype-Enriched Somatic Hypermutations Drive Affinity Maturation of a Public Human Antibody Targeting an Occluded Sarbecovirus Epitope”.
www.cell.com/cell-reports... [1/4]
Clonotype-enriched somatic hypermutations drive affinity maturation of a public human antibody targeting an occluded sarbecovirus epitope
Rao et al. demonstrate that convergent somatic hypermutations in the light chain,
enriched within a sarbecovirus-specific public antibody clonotype, drive affinity
maturation. This antibody targets a ...
www.cell.com
August 12, 2025 at 6:52 PM
🚨 New Publication!!!
I’m thrilled to share our latest study, “Clonotype-Enriched Somatic Hypermutations Drive Affinity Maturation of a Public Human Antibody Targeting an Occluded Sarbecovirus Epitope”.
www.cell.com/cell-reports... [1/4]
I’m thrilled to share our latest study, “Clonotype-Enriched Somatic Hypermutations Drive Affinity Maturation of a Public Human Antibody Targeting an Occluded Sarbecovirus Epitope”.
www.cell.com/cell-reports... [1/4]
SK bioscience in die globale klinische Phase 1/2-Entwicklung ist der erste derartige Impfstoff, der in klinische Studien eintritt, was ein vergleichsweise schnelles Entwicklungstempo beweist.
In einer von SK bioscience veröffentlichten Erklärung sagte CEO Jaeyong Ahn: „Die Entwicklung eines
In einer von SK bioscience veröffentlichten Erklärung sagte CEO Jaeyong Ahn: „Die Entwicklung eines
February 3, 2026 at 3:09 PM
SK bioscience in die globale klinische Phase 1/2-Entwicklung ist der erste derartige Impfstoff, der in klinische Studien eintritt, was ein vergleichsweise schnelles Entwicklungstempo beweist.
In einer von SK bioscience veröffentlichten Erklärung sagte CEO Jaeyong Ahn: „Die Entwicklung eines
In einer von SK bioscience veröffentlichten Erklärung sagte CEO Jaeyong Ahn: „Die Entwicklung eines
Really excited to have been a small part of this work investigating sarbecovirus host range, receptor usage and antigenicity!
www.biorxiv.org/content/10.1101/2025.09.03.673949v1
www.biorxiv.org/content/10.1101/2025.09.03.673949v1
Understanding the future risk of bat coronavirus spillover into humans: correlating sarbecovirus receptor usage, host range, and antigenicity.
Sarbecoviruses interact with their receptor, angiotensin converting enzyme 2 (ACE2), via the receptor binding domain (RBD) of Spike, the immunodominant target for neutralising antibodies. Understandin...
www.biorxiv.org
September 9, 2025 at 1:46 PM
Really excited to have been a small part of this work investigating sarbecovirus host range, receptor usage and antigenicity!
www.biorxiv.org/content/10.1101/2025.09.03.673949v1
www.biorxiv.org/content/10.1101/2025.09.03.673949v1
Among the sarbecovirus subgenus, SARS-CoV-2 is the only one so far discovered with a furin cleavage site at the S1-S2 junction.
It is also the only sarbecovirus to have caused a pandemic.
Further, several common cold CoVs have furin cleavage sites and so do other betacoronaviruses (the genus).
It is also the only sarbecovirus to have caused a pandemic.
Further, several common cold CoVs have furin cleavage sites and so do other betacoronaviruses (the genus).
June 3, 2024 at 11:51 PM
Among the sarbecovirus subgenus, SARS-CoV-2 is the only one so far discovered with a furin cleavage site at the S1-S2 junction.
It is also the only sarbecovirus to have caused a pandemic.
Further, several common cold CoVs have furin cleavage sites and so do other betacoronaviruses (the genus).
It is also the only sarbecovirus to have caused a pandemic.
Further, several common cold CoVs have furin cleavage sites and so do other betacoronaviruses (the genus).
So...
I learned what sarbecovirus is today.
I learned what sarbecovirus is today.
February 8, 2026 at 5:10 PM
So...
I learned what sarbecovirus is today.
I learned what sarbecovirus is today.
Anschließend werden in Phase 2 die Immunogenität und Sicherheit bei Erwachsenen und älteren Menschen untersucht, wobei der Prüfimpfstoff erneut mit Comirnaty verglichen wird. Zusätzlich werden kreuzreaktive Immunantworten innerhalb der Sarbecovirus-Familie, einschließlich
February 3, 2026 at 3:07 PM
Anschließend werden in Phase 2 die Immunogenität und Sicherheit bei Erwachsenen und älteren Menschen untersucht, wobei der Prüfimpfstoff erneut mit Comirnaty verglichen wird. Zusätzlich werden kreuzreaktive Immunantworten innerhalb der Sarbecovirus-Familie, einschließlich
Could we eventually have a vaccine that neutralizes many variants? Possibly. Researchers are working on pan-sarbecovirus or “universal” coronavirus vaccines that target conserved regions of the virus that mutate less.
March 7, 2026 at 2:15 PM
Could we eventually have a vaccine that neutralizes many variants? Possibly. Researchers are working on pan-sarbecovirus or “universal” coronavirus vaccines that target conserved regions of the virus that mutate less.
"A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice"
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice
The continued emergence of SARS-CoV-2 variants and the threat of future Sarbecovirus zoonoses have spurred the design of vaccines that can induce broa…
www.sciencedirect.com
November 18, 2024 at 7:07 PM
"A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice"
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Some promising news.
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
www.biospace.com/press-releas...
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
www.biospace.com/press-releas...
February 5, 2026 at 3:20 AM
Some promising news.
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
www.biospace.com/press-releas...
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
www.biospace.com/press-releas...
Either way, this data demonstrates that SARS-CoV-2 wasn’t a typical bat Sarbecovirus that jumped straight to humans; the mutations would not have been tolerated in that environment.
SARS-CoV-2 had been practicing for a while.
25/25
SARS-CoV-2 had been practicing for a while.
25/25
December 28, 2024 at 11:17 AM
Either way, this data demonstrates that SARS-CoV-2 wasn’t a typical bat Sarbecovirus that jumped straight to humans; the mutations would not have been tolerated in that environment.
SARS-CoV-2 had been practicing for a while.
25/25
SARS-CoV-2 had been practicing for a while.
25/25
I guess that means only one sacred cow is left standing - the furin cleavage site.
Let's see how the goal post will be moved once a sarbecovirus with a functional FCS is found in bats (or pangolins)... Give it time.
Let's see how the goal post will be moved once a sarbecovirus with a functional FCS is found in bats (or pangolins)... Give it time.
March 29, 2026 at 1:51 AM
I guess that means only one sacred cow is left standing - the furin cleavage site.
Let's see how the goal post will be moved once a sarbecovirus with a functional FCS is found in bats (or pangolins)... Give it time.
Let's see how the goal post will be moved once a sarbecovirus with a functional FCS is found in bats (or pangolins)... Give it time.
In fact, it had about as many reversions to the Sarbecovirus consensus that I’ve seen in a single cryptic.
5/
5/
March 23, 2026 at 12:14 AM
In fact, it had about as many reversions to the Sarbecovirus consensus that I’ve seen in a single cryptic.
5/
5/
Cool preprint with promising results for a next-gen SARS-CoV-2 (potentially pan-sarbecovirus) vaccine, but my major takeaway more than anything here is how potent the selection pressure to escape antibodies is for SARS-CoV-2 variants.
Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines
Vaccines against emerging SARS-CoV-2 variants and sarbecoviruses with pandemic potential must elicit a robust humoral immune response in a population imprinted with the SARS-CoV-2 spike (S) protein. H...
www.biorxiv.org
May 17, 2025 at 12:30 AM
Cool preprint with promising results for a next-gen SARS-CoV-2 (potentially pan-sarbecovirus) vaccine, but my major takeaway more than anything here is how potent the selection pressure to escape antibodies is for SARS-CoV-2 variants.
11/ Simply acquiring a furin cleavage motif therefore does not automatically make sarbecoviruses better at entering human respiratory cells. Yet if sarbecovirus spikes frequently benefit from a furin motif, why is SARS-CoV-2 the only known sarbecovirus that has one?
August 25, 2026 at 1:39 PM
11/ Simply acquiring a furin cleavage motif therefore does not automatically make sarbecoviruses better at entering human respiratory cells. Yet if sarbecovirus spikes frequently benefit from a furin motif, why is SARS-CoV-2 the only known sarbecovirus that has one?
zu erkennen, die in der gesamten Sarbecovirus-Familie konserviert sind, indem wir ihm gleichzeitig mehrere verwandte Antigene präsentieren“, sagte David Veesler @veeslerlab.bsky.social , Professor für Biochemie an der UW Medicine und Forscher am Howard Hughes Medical Institute, der die
February 3, 2026 at 3:06 PM
zu erkennen, die in der gesamten Sarbecovirus-Familie konserviert sind, indem wir ihm gleichzeitig mehrere verwandte Antigene präsentieren“, sagte David Veesler @veeslerlab.bsky.social , Professor für Biochemie an der UW Medicine und Forscher am Howard Hughes Medical Institute, der die
Overall, the lineage had a whopping 6 reversions to the consensus Sarbecovirus sequence. I believe this reflects adapting back to a GI environment.
6/
journals.plos.org/plospathogen...
6/
journals.plos.org/plospathogen...
June 19, 2025 at 5:55 PM
Overall, the lineage had a whopping 6 reversions to the consensus Sarbecovirus sequence. I believe this reflects adapting back to a GI environment.
6/
journals.plos.org/plospathogen...
6/
journals.plos.org/plospathogen...
Speaking of gain of function, the Nebraska lineage appeared 3 more times in the last month.
The SARS-CoV-2 Spike RBD looks more like a bat Sarbecovirus (RaTG13) than the Nebraska lineage.
Think our immune systems would recognize it?
The SARS-CoV-2 Spike RBD looks more like a bat Sarbecovirus (RaTG13) than the Nebraska lineage.
Think our immune systems would recognize it?
July 30, 2026 at 6:36 PM
Speaking of gain of function, the Nebraska lineage appeared 3 more times in the last month.
The SARS-CoV-2 Spike RBD looks more like a bat Sarbecovirus (RaTG13) than the Nebraska lineage.
Think our immune systems would recognize it?
The SARS-CoV-2 Spike RBD looks more like a bat Sarbecovirus (RaTG13) than the Nebraska lineage.
Think our immune systems would recognize it?
"we..infer ancestral..receptor binding domain..sequences across multiple Sarbecovirus clades and..[put in a] ..vaccine. Mice immunized .. are protected in the upper & lower resp tracts against..SARS-CoV-2.., SARS-CoV,..SHC014 & Pangolin/GD coronavirus strains"
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice
The continued emergence of SARS-CoV-2 variants and the threat of future Sarbecovirus zoonoses have spurred the design of vaccines that can induce broa…
www.sciencedirect.com
November 18, 2024 at 10:21 PM
"we..infer ancestral..receptor binding domain..sequences across multiple Sarbecovirus clades and..[put in a] ..vaccine. Mice immunized .. are protected in the upper & lower resp tracts against..SARS-CoV-2.., SARS-CoV,..SHC014 & Pangolin/GD coronavirus strains"
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
clinicaltrials.gov/study/NCT072...
clinicaltrials.gov/study/NCT072...
ClinicalTrials.gov
clinicaltrials.gov
February 4, 2026 at 5:43 AM
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
clinicaltrials.gov/study/NCT072...
clinicaltrials.gov/study/NCT072...